Technical Analysis for PHAS - PhaseBio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 3.58 -2.19% -0.08
PHAS closed down 2.19 percent on Friday, March 5, 2021, on 70 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical PHAS trend table...

Date Alert Name Type % Chg
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -2.19%
Wide Bands Range Expansion -2.19%
Down 3 Days in a Row Weakness -2.19%
Down 4 Days in a Row Weakness -2.19%
Older End-of-Day Signals for PHAS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Surgery Chemical Compounds Organic Compounds Hypertension Pulmonary Arterial Hypertension Reversal Orphan Disease Orphan Diseases Fusion Protein Platelet Pulmonary Hypertension Bio Pharmaceutical

Is PHAS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.85
52 Week Low 2.6
Average Volume 338,764
200-Day Moving Average 4.05
50-Day Moving Average 4.06
20-Day Moving Average 4.30
10-Day Moving Average 3.89
Average True Range 0.32
ADX 24.47
+DI 15.07
-DI 30.04
Chandelier Exit (Long, 3 ATRs ) 4.88
Chandelier Exit (Short, 3 ATRs ) 4.35
Upper Bollinger Band 5.30
Lower Bollinger Band 3.30
Percent B (%b) 0.14
BandWidth 46.63
MACD Line -0.15
MACD Signal Line -0.04
MACD Histogram -0.1067
Fundamentals Value
Market Cap 105.13 Million
Num Shares 29.4 Million
EPS -1.62
Price-to-Earnings (P/E) Ratio -2.21
Price-to-Sales 100.78
Price-to-Book 25.51
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.99
Resistance 3 (R3) 3.98 3.83 3.92
Resistance 2 (R2) 3.83 3.72 3.83 3.90
Resistance 1 (R1) 3.70 3.66 3.63 3.72 3.88
Pivot Point 3.55 3.55 3.51 3.56 3.55
Support 1 (S1) 3.43 3.45 3.35 3.44 3.28
Support 2 (S2) 3.28 3.38 3.28 3.26
Support 3 (S3) 3.15 3.28 3.24
Support 4 (S4) 3.17